<?xml version='1.0' encoding='utf-8'?>
<record xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
			<header>
				<identifier>oai:bovine-ojs-tamu.tdl.org:article/4468</identifier>
				<datestamp>2020-02-06T08:56:43Z</datestamp>
				<setSpec>aabp:Post</setSpec>
			</header>
			<metadata>
<oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/  http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
	<dc:title xml:lang="en">Comparing Cytopathic and Noncytopathic Bovine Viral Diarrhea Virus (BVDV) Vaccines: Antigen Trafficking Increased to Mucosal Surfaces with Noncytopathic Vaccines</dc:title>
	<dc:creator xml:lang="en">Chase, C. C. L.</dc:creator>
	<dc:creator xml:lang="en">Braun, L. J.</dc:creator>
	<dc:creator xml:lang="en">Holler, L.</dc:creator>
	<dc:creator xml:lang="en">Spire, M.</dc:creator>
	<dc:subject xml:lang="en">Bovine viral diarrhea virus</dc:subject>
	<dc:subject xml:lang="en">BVDV</dc:subject>
	<dc:subject xml:lang="en">respiratory disease</dc:subject>
	<dc:subject xml:lang="en">reproductive disease</dc:subject>
	<dc:subject xml:lang="en">mucosal immunity</dc:subject>
	<dc:subject xml:lang="en">parenteral vaccines</dc:subject>
	<dc:subject xml:lang="en">noncytopathic</dc:subject>
	<dc:subject xml:lang="en">cytopathic</dc:subject>
	<dc:description xml:lang="en">Bovine viral diarrhea virus (BVDV) is a major pathogen of cattle causing severe respiratory and reproductive disease. Since BVDV infects through the oral-nasal route, increasing mucosal immunity should decrease BVDV infection and disease. This makes parenteral vaccines that can traffic antigens to mucosal lymphoid tissue more advantageous for generating mucosal immunity. This study was aimed at the distribution of bovine viral diarrhea virus (BVDV) in tissues following vaccination with one of three commercial vaccines: two vaccines containing cytopathic (CP) BVDV viruses and one vaccine containing noncytopathic (NCP) BVDV virus.</dc:description>
	<dc:publisher xml:lang="en">American Association of Bovine Practitioners</dc:publisher>
	<dc:date>2008-09-25</dc:date>
	<dc:type>info:eu-repo/semantics/article</dc:type>
	<dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
	<dc:format>application/pdf</dc:format>
	<dc:identifier>https://bovine-ojs-tamu.tdl.org/aabp/article/view/4468</dc:identifier>
	<dc:identifier>10.21423/aabppro20084468</dc:identifier>
	<dc:source xml:lang="en">American Association of Bovine Practitioners  Conference Proceedings; 2008; 274</dc:source>
	<dc:source>1079-9737</dc:source>
	<dc:language>eng</dc:language>
	<dc:relation>https://bovine-ojs-tamu.tdl.org/aabp/article/view/4468/4375</dc:relation>
	<dc:rights xml:lang="en">Copyright (c) 2008 American Association of Bovine Practitioners</dc:rights>
</oai_dc:dc>
			</metadata>
		</record>
		
